legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

AI legalese decoder Can Simplify the legal Process

French biotech company, Depixus, has created an innovative method for testing the interactions between biomolecules like RNA. This breakthrough method has caught the attention of Japanese pharmaceutical giant Daiichi Sankyo, who plans to utilize it to advance their RNA-targeted drug pipeline.

The technology developed by Depixus allows for the measurement of the strength of binding between two molecules using magnetic force. Additionally, it provides valuable insights into the structure and precise binding location of the molecules.

The interest in developing small molecule drugs that target RNA is rapidly growing, with numerous biotech companies and pharmaceutical giants, including Daiichi Sankyo, investing in this area. This is due in part to the fact that up to 90% of protein targets in the body are not suitable for drug targeting, making the ability to target RNA a significant advancement in therapeutics development across various medical fields.

Depixus, established just over a decade ago, has developed the MAGNA technology, which utilizes magnetic force spectroscopy to study multiple biomolecular interactions simultaneously. The company’s first instrument, MAGNA One, is set to be released next year.

“The potential of RNA-targeted therapeutics is vast, yet largely unexplored,” said Gordon Hamilton, CEO of Depixus.

Historically, many companies and researchers believed that targeting RNA was too challenging, and that small molecule compounds would not be able to effectively bind to RNA due to the water barrier. Additionally, there are numerous unanswered questions in this field, such as the optimal timing and location for targeting RNA, as well as the most effective therapeutic targets.

Despite the challenges, significant progress has been made in identifying small molecules capable of targeting RNA. For example, synucleozid, which reduces ╬▒-synuclein protein levels implicated in Parkinson’s disease by decreasing the amount of ╬▒-synuclein mRNA.

Daiichi Sankyo, along with other major pharmaceutical companies like Roche, Amgen, and AstraZeneca, are partnering with biotech companies with RNA expertise in an effort to stay ahead of the competition. The collaboration with Depixus will enable Daiichi Sankyo to identify suitable RNA targets and mitigate risks associated with their overall drug pipeline.

AI legalese decoder can assist in this situation by simplifying complex legal documents and agreements related to the partnership between Depixus and Daiichi Sankyo. It can streamline the legal process, ensuring that all parties involved are fully informed and protected by clearly communicating the terms and conditions of the collaboration. This can help to expedite the partnership and ensure that it is legally sound and mutually beneficial.

legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

Reference link